( October 23, 2026, 05:38 GMT | Official Statement) -- MLex Summary: India-based pharmaceutical company Sun Pharma’s proposed acquisition of US-based Organon is under review by Australia's competition watchdog. The Australian Competition & Consumer Commission on Thursday said the companies overlap in Australia in the supply of several medicines, including antidepressants, antipsychotics, migraine treatments and fertility drugs used in IVF. To address competition concerns involving the IVF drug ganirelix acetate, Sun Pharma has agreed to grant Ferring Pharmaceuticals exclusive rights to commercialize and distribute its generic product in Australia from December, although Sun Pharma will continue manufacturing it, the watchdog said. Submissions are due by Oct. 30.Statement follows. Questionnaire attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.